Last reviewed 2026-04-23 · How we verify

Mega Resveratrol® capsules

Sun Yat-sen University · Phase 3 active Small molecule

Mega Resveratrol® capsules is a Polyphenolic antioxidant / Sirtuin activator Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 3 development for Cardiovascular health and endothelial function, Age-related cognitive decline and neuroprotection.

Resveratrol acts as a polyphenolic antioxidant and sirtuin activator that reduces oxidative stress and modulates cellular signaling pathways involved in aging and disease.

Resveratrol acts as a polyphenolic antioxidant and sirtuin activator that reduces oxidative stress and modulates cellular signaling pathways involved in aging and disease. Used for Cardiovascular health and endothelial function, Age-related cognitive decline and neuroprotection.

Likelihood of approval

55.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Mega Resveratrol® capsules
Sponsor	Sun Yat-sen University
Drug class	Polyphenolic antioxidant / Sirtuin activator
Target	SIRT1, general antioxidant pathways, AMPK
Modality	Small molecule
Therapeutic area	Cardiovascular, Neurology, Anti-aging, General wellness
Phase	Phase 3

Mechanism of action

Resveratrol is a naturally occurring polyphenol found in grapes and red wine that functions primarily through antioxidant activity and activation of sirtuins (NAD+-dependent deacetylases), particularly SIRT1. These mechanisms promote cellular stress resistance, mitochondrial function, and anti-inflammatory responses. The compound also modulates multiple signaling pathways including AMPK and NF-κB, contributing to potential cardioprotective, neuroprotective, and anti-aging effects.

Approved indications

Cardiovascular health and endothelial function
Age-related cognitive decline and neuroprotection

Common side effects

Gastrointestinal upset
Headache
Nausea

Key clinical trials

A Dose-response Study of Dietary Resveratrol on Lipid Metabolism Disorder (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Mega Resveratrol® capsules CI brief — competitive landscape report
Mega Resveratrol® capsules updates RSS · CI watch RSS
Sun Yat-sen University portfolio CI

Frequently asked questions about Mega Resveratrol® capsules

What is Mega Resveratrol® capsules?

Mega Resveratrol® capsules is a Polyphenolic antioxidant / Sirtuin activator drug developed by Sun Yat-sen University, indicated for Cardiovascular health and endothelial function, Age-related cognitive decline and neuroprotection.

How does Mega Resveratrol® capsules work?

Resveratrol acts as a polyphenolic antioxidant and sirtuin activator that reduces oxidative stress and modulates cellular signaling pathways involved in aging and disease.

What is Mega Resveratrol® capsules used for?

Mega Resveratrol® capsules is indicated for Cardiovascular health and endothelial function, Age-related cognitive decline and neuroprotection.

Who makes Mega Resveratrol® capsules?

Mega Resveratrol® capsules is developed by Sun Yat-sen University (see full Sun Yat-sen University pipeline at /company/sun-yat-sen-university).

What drug class is Mega Resveratrol® capsules in?

Mega Resveratrol® capsules belongs to the Polyphenolic antioxidant / Sirtuin activator class. See all Polyphenolic antioxidant / Sirtuin activator drugs at /class/polyphenolic-antioxidant-sirtuin-activator.

What development phase is Mega Resveratrol® capsules in?

Mega Resveratrol® capsules is in Phase 3.

What are the side effects of Mega Resveratrol® capsules?

Common side effects of Mega Resveratrol® capsules include Gastrointestinal upset, Headache, Nausea.

What does Mega Resveratrol® capsules target?

Mega Resveratrol® capsules targets SIRT1, general antioxidant pathways, AMPK and is a Polyphenolic antioxidant / Sirtuin activator.

Drug class: All Polyphenolic antioxidant / Sirtuin activator drugs
Target: All drugs targeting SIRT1, general antioxidant pathways, AMPK
Manufacturer: Sun Yat-sen University — full pipeline
Therapeutic area: All drugs in Cardiovascular, Neurology, Anti-aging, General wellness
Indication: Drugs for Cardiovascular health and endothelial function
Indication: Drugs for Age-related cognitive decline and neuroprotection

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing